Digital Fitness Market Potential Risks and Comprehensive Competitive Strategy Analysis in Different Fields, Report 2020 to 2025

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Digital Fitness Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Digital Fitness Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Digital Fitness market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Digital Fitness industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16706715

In Regional Analysis, the Digital Fitness market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Digital Fitness market throughout the forecast length. The Digital Fitness market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Digital Fitness Market: – https://www.industryresearch.co/enquiry/request-covid19/16706715

Digital Fitness market report provides in-depth data about company Profiles, Digital Fitness launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Digital Fitness market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Digital Fitness market covered in report:

● Garmin, Ltd ● Samsung Electronics Co. Ltd ● Casio ● Fitbit, Inc ● Adidas AG ● Huawei ● Fossil ● Xiaomi ● TicWatch ● Apple, Inc

On the basis of types, the Digital Fitness market from 2015 to 2025 is primarily split into:

● Smartwatches ● Fitness Wristbands ● Smart Clothing ● Smart Shoes ● Others

On the basis of applications, the Digital Fitness market from 2015 to 2025 covers:

● Fitness ● Sports

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16706715

Digital Fitness Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Digital Fitness Market report describes present situation, historical background and future forecast. It Comprehensive data showing Digital Fitness sale, consumption, trade statistics, and prices in the recent years are provided. The Digital Fitness report indicates a wealth of information on Digital Fitness vendors. Digital Fitness Market forecast for next five years, including Market volumes and prices is also provided. Raw Material Supply and Downstream Consumer Information is also included.

At last, report on Digital Fitness Market is a comprehensive analysis of the Market providing

Read more

How digital healthcare tools are changing medicine in Europe since COVID-19

Like in America, the healthcare industry is also making shifts to adopt new, safer hospital practices in response to Covid-19. Since physical contact and proximity present such risks, hospitals are turning to a variety of digital tools in order to meet their care priorities, such as risk reduction and better resource utilization. Having a better understanding of these priorities and what tools hospitals are using now will help us in the health tech industry know what to build for them next.

At Siilo, we believe that putting tried and true technology into the hands of healthcare professionals will result in a higher quality of care for patients down the line. Here are the three major categories of care currently being aided by digital tools: distance diagnoses, internal communications, and external collaborations.

Distance diagnoses
Covid-19 was not the start of the telehealth revolution, but it was certainly a major driver in its widespread adoption this year. While doctors and specialists could not and still cannot see their patients in person, that doesn’t mean people haven’t stopped needing consultations. Moving diagnoses online has been the only option to continue delivering care directly to patients.

Companies like Germany’s Klara are working to put these digital tools at the center of doctor-patient communication all across Europe. Telehealth services provide a variety of benefits: anything from patient portals, where individuals can email their doctors in a secure online environment, to mobile applications, allowing doctors to hold virtual appointments with patients via video call. They can also include the collection of health data, voluntarily given by patients, through the Internet of Things, such as smartwatches, in order to get a more holistic view of the patient’s wellbeing.

Advances in telehealth can certainly ease the burdens on healthcare professionals looking to safely diagnose their patients over digital platforms, but we need to make sure that we are providing products that prioritize data safety. That means designing for GDPR compliance incorporating key features, like passcode protection and device-only data storage.

Internal Communications
The influx of telehealth and digital solutions for communicating with patients has also resulted in a professional counterpart for members of medical institutions, organizations, and associations all across Europe. Beyond the EHRs and secure email servers typically found in hospitals or physicians’ offices, technology is being developed to make communication by modern healthcare professionals more efficient, more secure, and more informative.

People bring their smartphones to work with them, and as such, we see professionals increasingly seeking out mobile tools and applications to simplify their workflows. In particular, professionals are looking for ways to quickly exchange information with each other and their departments at large. My company, Siilo works in this space.

This integration is not seamless, however. Bring-your-own-device policies, such as those found in Germany and France, have been put in place to limit the chances of cross-contaminating patient data and personal information, and increasing digital literacy amongst professionals can be a difficult and time-consuming endeavor. Nevertheless, hospitals and public health institutions should be prepared

Read more

3 Reasons Why The Digital Fitness Boom Is Here To Stay

Digital fitness was already poised for strong growth for the foreseeable future, but the COVID-19 crisis will likely accelerate the use of digital fitness and create long-term changes

Grow Your Business, Not Your Inbox

Stay informed and join our daily newsletter now!


3 min read

Opinions expressed by Entrepreneur contributors are their own.


You’re reading Entrepreneur India, an international franchise of Entrepreneur Media.

The COVID-19 pandemic brought about unanticipated impacts both personally and professionally. While the near-term promises to be extremely challenging for us, as we try and adapt to the situation around—this ‘new normal’ of sorts, the long-term effects will be those where we come out stronger together.

Health and fitness-wise, the industry also has gone through its fair bit of change. The largest being the rise of ‘digital fitness’ from the comforts of your own home. Digital fitness was already poised for strong growth for the foreseeable future, but the COVID-19 crisis will likely accelerate the use of digital fitness and create long-term changes in how consumers manage their overall wellbeing.

Willingness To Experiment

Given COVID-19 and the lockdown that the country went through, the fitness enthusiasts—both young and old—across the world have been pushed to try at least some form of digital fitness solutions even if they have been hesitant to do so in the past.

Our smartphones have become our on-demand devices for everything including our fitness regime. People now can have a personal trainer in their pockets for an amazing workout, anytime, anywhere. I believe that this trend is here to stay and even though a lot of the members will eventually go back to using the gyms, the digital boom will remain. For businesses, it will be important to have both physical plus digital services available to their customers.

Flexibility & Convenience

While physical gyms and studios have you plan your workout routine around them, digital fitness solutions give you the freedom to work out when you want, where you want and with whom you want. This convenience factor plus the fact that you are within the comfort of your own home is a major advantage to fitness enthusiasts who lead a hectic work life or anyone looking to exercise at home.

These recent developments in the digital fitness space along with customer’s readiness to adopt shows us that digital fitness and wellness solutions are here to stay.

Accountability & Gamification With Your Tribe

We as humans are competitive by nature. Fitness is no different. Introducing gamification elements such as badges, leaderboards, competition and levels drive up motivation amongst fitness enthusiasts. This pushes us to be the best version of ourselves and makes us accountable to the people whom we work out with  our buddies, our tribe! What also drives us, is being surrounded by the people we love. Working out with the people we love, pushes us to do our best. Social media platforms such as Instagram and Facebook, streaming platforms like Zoom, Hangout and interactive chat mediums such as

Read more

Digital Medicine Market Size Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 24, 2020 (Market Insight Reports) —
Selbyville, Delaware. Market Study Report LLC: A comprehensive research study on Digital Medicine market added by Market Study Report LLC provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Digital Medicine market in terms of the demand landscape, driving factors and growth strategies adopted by market players.

This report presents a comprehensive overview, market shares, and growth opportunities of Digital Medicine market by product type, application, key manufacturers and key regions and countries.

Digital medicine technology is an innovative technological technique that has bridged the gap among the healthcare and digital technology. Due to advancement in health care, scientific medicine is pioneered the concept of digital medicine that aims in supporting individualized medicine by recognizing the biology of a patient via a wireless sensor technology and other technologies related to mobile health. Digital medicine is more privileged than recent medical practice as it is more effective, precise, feasible and well distributed technology. Growing healthcare expenditure, high penetration of smartphones, along with high percentage of population with chronic diseases are the few factor responsible for high CAGR of the market over the forecast period.

Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/2495936/?utm_source=Marketwatchtm.com/&utm_medium=AK

Major market player included in this report are:

2Morrow

Ginger

Akili Interactive

Livongo

AliveCor

WellDoc

Mocacare

Proteus Digital Health Voluntis

Omada Health

Digital Medicine Market outlook: Apart from exploring into the various segments, the report clustered on key Digital Medicine Market trends and sectors that are either driving or averting the growth of the Digital Medicine industry. Growth policies and plans are mentioned likewise as producing processes and cost structures also are analyzed. The Digital Medicine Market industry development trends are studied through both secondary and primary sources. Finally, the feasibility of the latest investment comes is assessed and overall analysis conclusions offered in Digital Medicine market analysis report.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Mobile Health

EMR/EHR

Telehealth

Wireless Health

By Application:

Diabetes

Mental Health

Heart Diseases

Others

Research objectives

To study and analyze the global Digital Medicine market size by key regions/countries, type and application, history data from 2016 to 2017, and forecast to 2026.

To understand the

Read more

Top Names in Digital Medicine to Headline NODE.Health Conference

NEW YORK, Nov. 24, 2020 /PRNewswire-PRWeb/ — NODE.Health, the association for digital medicine, has announced the agenda for the 2020 NODE.Health Digital Medicine Conference December 7th to 11th, and it features some of the best minds in digital medicine with 5 days of virtual content highlighting evidence, innovation and highly relevant COVID related information.

It also kicks off with a full day of educational content on Sunday, December 6th as part of the Digital Medicine Foundation Certificate Course worth up to 12 AMA PRA Category 1 Credit(s)™. The course, which includes an all day session on December 6th along with free electives during the conference, is targeted at exposing leaders, students and clinicians in all specialties to learn the fundamentals of digital medicine. It is also intended to complement the more advanced topics throughout the Conference the following week.

Together, the conference and the course include over 70+ speakers and faculty representing the FDA, health systems, pharma, payors, and technology innovators, and will feature several keynote speakers who are on the front lines of digital medicine transformation:

Leana Wen, MD, MSc is a Visiting Professor of Health Policy and Management at The George Washington University and practicing emergency medicine physician. As a columnist for The Washington Post, Dr. Wen contributes articles on health policy. She is also a medical analyst and on-air commentator for CNN and is recognized globally for her expertise and leadership in pandemic preparedness and response as a Former Health Commissioner for the City of Baltimore. She will present the session: “Keynote: Year in Review – The Year Public Health and Population Health Became One and What that Means for the Future of Healthcare.”

Syra Madad, DHSc, MSc, MCP is Senior Director, System-wide Special Pathogens Program and Principle Investigator (PI) of NYC Health + Hospitals Institute for Diseases and Disaster Management at New York City Health + Hospitals. A leading epidemiologist and public health expert in special pathogen preparedness and response, she is Safety Lead of the Enhanced Special Investigations Unit of NYC Test & Trace Corps. She will present the session: “The Evidence Behind the Quest for a Vaccine”.

John Brownstein, PhD is Chief Innovation Officer at Boston Children’s Hospital and Professor of Medicine at the Harvard Medical School. An internationally-recognized leader in global disease outbreak tracking, his research focuses on applying computational epidemiology for public health and has resulted in the development of multiple public health surveillance systems, including HealthMap. He will present the session: “Keynote: Part II: Separating the Signal from the Noise for COVID Related Innovations.”

Ashish Jha, MD, MPH is Dean of the Brown University School of Public Health. A practicing general internist and health policy expert, he conducts research on public health policy outcomes and quality and cost of health care. Previously, he was Director of the Harvard Global Health Institute (HGHI) and the K.T. Li Professor of Global Health at the Harvard T.H. Chan School of Public Health. He will present the

Read more

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian

Read more

Why a digital Christmas goes against our instincts

Even at the best of times, Christmas can be a season of contradictory feelings. There is a yearning to enjoy the season of goodwill with our relatives and yet their proximity often creates friction. For many families, it is the only time of year we get to spend together, yet we resent the stress that this creates.

The Covid-19 pandemic will only amplify this angst. It is hard to predict how the situation will change, but it seems unlikely that the second wave will have receded by 25 December. If the virus is still circulating widely, our celebrations will pose a danger and we will have to decide between taking that risk and celebrating alone. Boris Johnson has repeatedly asserted the government will do “everything we can to make sure that Christmas for everybody is as normal as possible”, yet his chief scientific advisor Sir Patrick Vallance echoed the warning of a senior Scottish health official that a “digital Christmas” cannot be ruled out.

Why would we be prepared to put our ourselves and our loved ones at risk for the sake of turkey and charades?

These traditions are deeply embedded in our culture, but recent developments in evolutionary psychology suggest the knotty and conflicting emotions they inspire may have deeper origins. While it cannot provide simple solutions to our dilemmas, a knowledge of our evolved instincts may help us to approach Christmas with a little more clarity of thought.

According to evolutionary theorists, most of our social connections rely on a sense of reciprocity that brings mutual benefits. In prehistory, we might have shared our food with allies during times of scarcity in the knowledge that they would do the same for us; the balance of give and take is essential for the survival of the relationship. “Implicitly or explicitly, people keep track of favours given to friends, even close friends,” says Dr Samuel Roberts at Liverpool John Moores University.

Related: Victoria Derbyshire apologises over Covid Christmas comments

For family members, however, we have an additional motivation for altruism, arising from an evolutionary process known as “kin selection”. This theory, popularised in Richard Dawkins’s book The Selfish Gene, centres on the fact that our close relatives – our siblings, nieces, nephews and grandchildren – share many of our genes. By aiding our nearest kin, we can therefore protect part of our genetic lineage. “In evolutionary terms, I can pass on my genes through my own kids or by helping out my sister and her kids,” says Roberts. This means we have evolved an instinctual urge to care more about family members than friends, even if we share little in common besides our genes – and we don’t keep such a close watch on the reciprocal give and take.

Although the theory of kin selection may seem too cynical and simplistic to explain human behaviour, there is strong evidence it drives many of our feelings and actions. Working with Robin Dunbar and Oliver Curry at the University of Oxford,

Read more

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.    

Logo
Logo

Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function

Read more

Philips and Singapore General Hospital (SGH) to establish Digital and Computational Pathology Center of Excellence

Digital pathology at Singapore General Hospital

October 23, 2020

  • SGH aims to develop the first fully digitized histopathology laboratory in ASEAN by expanding the use of Philips’ IntelliSite Pathology Solution, potentially increasing the productivity of existing staff by 7%

  • Philips Singapore and SGH will optimize digital pathology use to facilitate research in Artificial Intelligence (AI)

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration with Singapore General Hospital (SGH) to establish the Singapore General Hospital Digital and Computational Pathology Center of Excellence. The SGH Center of Excellence aims to advance pathology practice by implementing a fully digital histopathology workflow and deploying Artificial Intelligence (AI) to increase productivity and enhance patient care.

Located within SGH’s Division of Pathology, one of the largest pathology laboratories in ASEAN, the Center of Excellence aims to establish ASEAN’s first fully digitized histopathology laboratory by expanding its digital pathology capabilities for primary diagnosis, training, and R&D with the Philips IntelliSite Pathology Solution. Both SGH and Philips will also work closely on other diverse areas, including streamlining of the histopathology laboratory’s digital workflow.

As in other parts of the world, the demand for cancer diagnosis in Singapore is increasing while pathologists remain scarce. A recent study, conducted by SGH and Philips, revealed that full digitization of SGH’s histopathology laboratory will improve efficiency. It has the potential to enable time savings in the pathology workflow and allow the pathology department to increase its capacity by another 7% whilst retaining the same number of employees.

Through optimization of digital pathology at SGH, the hospital will be able to further its research in AI. AI-based tools can aid pathologists in diagnosing diseases such as cancer – the leading cause of mortality in Singapore [1] – and empower them to face the current challenges in pathology. The increasing number of cancer cases, an aging population, and rapid advances in personalized medicine have resulted in significant complexity of pathological diagnostics, adding to the workload of pathologists. AI will allow pathologists to focus more on challenging tasks and unusual cases that require a higher degree of expertise and skills.

“As healthcare becomes more complex and demanding, digitization has become a key enabler for the Hospital to provide better care for our patients and to be more efficient,” said Prof. Kenneth Kwek, Chief Executive Officer at SGH. “Digital pathology is an example of that. Our partnership with companies such as Philips, with its clinical and technical know-how, is important in helping us achieve our goal.”

“Digital pathology enhances the quality and efficiency of a histopathology laboratory,” said Diederik Zeven, General Manager, Health Systems, Philips ASEAN Pacific. “We are committed to partnering with leading healthcare institutions like Singapore General Hospital to bring the latest in precision diagnosis and AI capabilities to help them augment clinical quality, improving patient outcomes and thereby reducing the cost of care.”

Philips IntelliSite Pathology Solution enables pathologists to review and interpret digital images of surgical pathology

Read more

Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, announced today the presentation of new clinical data on an improved tablet formulation of its liver-distributed farnesoid X receptor (FXR) agonist TERN-101 at the Paris NASH Digital Experience, taking place virtually October 22-23, 2020. The presentation, entitled “Comparative pharmacokinetics of two oral formulations of nonsteroidal farnesoid X receptor agonist TERN-101 in healthy volunteers,” demonstrated that an amorphous tablet formulation of TERN-101, which is currently being evaluated in the Phase 2a LIFT study in NASH patients, achieved faster absorption and higher plasma levels compared to a previous crystalline capsule formulation of TERN-101. The study results also demonstrate that the new formulation reduces pharmacokinetic variability and that TERN-101 can be administered without regard to food.

“In Terns’ Phase 1 studies, TERN-101 has demonstrated potent FXR activation in the liver and is well tolerated, with no observation of pruritus and no difference from placebo in serum lipid effects. We’ve now developed an improved formulation that optimizes absorption and minimizes PK variability,” said Erin Quirk, M.D., President and Chief Medical Officer of Terns. “This new TERN-101 formulation is now being studied in our 12-week Phase 2a LIFT study in NASH patients, and we look forward to seeing the results in mid-2021.”

Full details from the presentation can be found at www.ternspharma.com/scientific-publications.

About TERN-101 and Farnesoid X Receptor (FXR) Agonism

TERN-101 is a potent, non-steroidal FXR agonist, with enhanced liver distribution being developed for the treatment of NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. FXR agonism has demonstrated improvement over placebo in regression of histological liver fibrosis without progression of NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NASH. TERN-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of NASH.

About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases. The company’s liver-selective FXR-agonist, TERN-101, is currently conducting a multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate efficacy, safety, and pharmacokinetics in 96 presumed NASH patients who receive placebo or TERN-101 at various dose levels for 12 weeks. Terns recently announced positive Phase 1 clinical data for its highly selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. In addition,

Read more